Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 3, 2007, Pages 535-545

  Bucki, Robert ^a   Sostarecz, Audra Goach ^a,c   Byfield, Fitzroy J ^a   Savage, Paul B ^b   Janmey, Paul A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Brigham Young University   (United States)

^c MONMOUTH COLLEGE   (United States)

Author keywords

Cathelicidin; Lipopolysaccharide; Nuclear factor B

Indexed keywords

ANTIINFECTIVE AGENT; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CERAGENIN CSA 13; DNA; DORNASE ALFA; F ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KANAMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN HB 71; PROTEIN WLBU 2; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG DNA INTERACTION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INFECTION; INFLAMMATION; LIGHT SCATTERING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN TRANSPORT; PSEUDOMONAS AERUGINOSA;

ACTINS; ADULT; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIA; CELL LINE; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DNA; DRUG RESISTANCE, BACTERIAL; ELECTROLYTES; ENDOTHELIAL CELLS; ERYTHROCYTES; HEMOLYSIS; HUMANS; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ATOMIC FORCE; PEPTIDES; SPUTUM; STEROIDS; TEICHOIC ACIDS;

EID: 34548131220     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm218     Document Type: Article

References (47)

1. Heeckeren A, Walenga R, Konstan MW et al. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997; 100: 2810-5.
2. Tirouvanziam R, de Bentzmann S, Hubeau C et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000; 23: 121-7.
3. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51.
4. Travis SM, Conway BA, Zabner J et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999; 20: 872-9.
5. Smith JJ, Travis SM, Greenberg EP et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-36.
6. Bals R, Weiner DJ, Meegalla RL et al. Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol 2001; 25: 21-5.
7. Tang JX, Wen Q, Bennett A et al. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol 2005; 289: L599-605.
8. Felgentreff K, Beisswenger C, Griese M et al. The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 2006; 12: 3100-6.
9. Ulmer JS, Herzka A, Toy KJ et al. Engineering actin-resistant human DNase I for treatment of cystic fibrosis. Proc Natl Acad Sci USA 1996; 93: 8225-9.
10. Vasconcellos CA, Allen PG, Wohl ME et al. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263: 969-71.
11. Tang JX, Janmey PA. The polyelectrolyte nature of F-actin and the mechanism of actin bundle formation. J Biol Chem 1996; 271: 8556-63.
12. Walker TS, Tomlin KL, Worthen GS et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 2005; 73: 3693-701.
13. Ernst RK, Yi EC, Guo L et al. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 1999; 286: 1561-5.
14. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003; 28: 738-45.
15. Hancock RE, Patrzykat A. Clinical development of cationic antimicrobial peptides: From natural to novel antibiotics. Curr Drug Targets Infect Disord 2002; 2: 79-83.
16. Zhang L, Parente J, Harris SM et al. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 2921-7.
17. Saiman L, Tabibi S, Starner TD et al. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 2838-44.
18. Deslouches B, Islam K, Craigo JK et al. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: Implications for systemic applications. Antimicrob Agents Chemother 2005; 49: 3208-16.
19. Bartlett KH, McCray PS, Jr, Thorne PS. Reduction in the bactericidal activity of selected cathelicidin peptides by bovine calf serum or exogenous endotoxin. Int J Antimicrob Agents 2004; 23: 606-12.
20. De Y, Chen Q, Schmidt AP et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192 1069-74.
21. Bowdish DM, Davidson DJ, Lau YE et al. Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2005; 77: 451-9.
22. Shaykhiev R, Beisswenger C, Kandler K et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 2005; 289: L842-8.
23. Savage PB, Li C, Taotafa U et al. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002; 217: 1-7.
24. Zanetti M, Gennaro R, Scocchi M et al. Structure and biology of cathelicidins. Adv Exp Med Biol 2000; 479: 203-18.
25. Bucki R, Pastore JJ, Randhawa P et al. Antibacterial activities of rhodamine B-oonjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. Antimicrob Agents Chemother 2004; 48: 1526-33.
26. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
27. Boman HG. Antibacterial peptides: Basic facts and emerging concepts. J Intern Med 2003; 254: 197-215.
28. Ding B, Guan Q, Walsh JP et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem 2002; 45: 663-9.
29. Savage PB, Chambers HF, Genberg C et al. Activity of a novel cationic steroid antimicrobial (CSA-13) against Staphylococcus aureus and bacterial species associated with infection in cystic fibrosis patient. 2005; www.ceragenix.com/pdf/JMI2.pdf; Poster F-1232.
30. Kronborg G. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS 1995; 50 Suppl: 1-30.
31. Silvestro L, Weiser JN, Axelsen PH. Antibacterial and antimembrane activities of cecropin A in Escherichia coli. Antimicrob Agents Chemother 2000; 44: 602-7.
32. Giacometti A, Cirioni O, Greganti G et al. In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. Antimicrob Agents Chemother 1998; 42: 3320-4.
33. Bucki R, Georges PC, Espinassous Q et al. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 2005; 44: 9590-7.
34. Doktycz MJ, Sullivan CJ, Hoyt PR et al. AFM imaging of bacteria in liquid media immobilized on gelatin coated mica surfaces. Ultramicroscopy 2003; 97: 209-16.
35. Bucki R, Janmey PA. Interaction of the gelsolin-derived antibacterial PBP10 peptide with lipid bilayers and cell membranes. Antimicrob Agents Chemother 2006; 50: 2932-40.
36. van Langevelde P, Ravensbergen E, Grashoff P et al. Antibiotic-induced cell wall fragments of Staphylococcus aureus increase endothelial chemokine secretion and adhesiveness for granulocytes. Antimicrob Agents Chemother 1999; 43: 2984-9.
37. Oren Z, Lerman JC, Gudmundsson GH et al. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: Relevance to the molecular basis for its non-cell-selective activity. Biochem J 1999; 341: 501-13.
38. Henzler Wildman KA, Lee DK, Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 2003; 42: 6545-58.
39. Grant NJ, Oriol-Audit C. Influence of the polyamine spermine on the organization of cortical filaments in isolated cortices of Xenopus laevis eggs. Eur J Cell Biol 1985; 36: 239-46.
40. DeRouchey J, Netz RR, Radler JO. Structural investigations of DNA-polycation complexes. Eur Phys J E Soft Matter 2005; 16: 17-28.
41. Hunt BE, Weber A, Berger A et al. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 1995; 39: 34-9.
42. Eisenberg JM, Pepe J, Williams-Warren M et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 1997; 111: 955-62.
43. Gazit E, Boman A, Boman HG. Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. Biochemistry 1995; 34: 11479-88.
44. Otves L, Jr, Rogers ME, Consolvo PJ et al. Interaction between heat shook proteins and antimicrobial peptides. Biochemistry 2000; 39: 14150-9.
45. Mookherjee N, Brown KL, Bowdish DM et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006; 176: 2455-64.
46. Erridge C, Bennett-Guerrero E, Poxton IR. Structure and function of lipopolysaccharides. Microbes Infect 2002; 4: 837-51.
47. Rinaldi AC, Mangoni ML, Rufo A et al. Temporin L: Antimicrobial, haemolytic and cytotoxic activities, and effects on membrane permeabilization in lipid vesicles. Biochem J 2002; 368: 91-100.